Positive results of selinexor, bortezomib, and dexamethasone in myeloma patients who have received one to three prior lines of therapy

 

New data of the phase 3 Boston clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from 29 to 31 May 2020. This study evaluates weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in myeloma patients who have received one to three prior lines of therapy.

Selinexor is being explored also in combination with other myeloma drugs. New data of these combinations are being presented in the 25th European Hematology Association (EHA) Annual Congress which is happening virtual from 11 to 21 June.

Myeloma Patients Europe (MPE) has interviewed Prof Dr Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Greece, and lead author of the Boston study to summarise the main results presented at ASCO 2020 and analyse what we can expect from this drug in the near future.

 

Find below this video or watch it on our YouTube Channel:

 

[embedyt] https://www.youtube.com/watch?v=Cdw5j4rv_4Y&width=550&height=309&iv_load_policy=3&centervid=1&rel=0&showinfo=0[/embedyt]